Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases

AI Summary

A phase 3 trial found that patients receiving high-dose eicosapentaenoic acid (EPA) around surgery for colorectal cancer liver metastases had longer overall survival than patients receiving placebo. The results were presented at the ESMO Congress 2026 in Madrid.

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026, held in Madrid Oct. 23–27.